Background {#Sec1}
==========

Peripheral neuropathy symptoms often persist after chemotherapy treatment has finished, and they can significantly impair patients' quality of life, even in the long term \[[@CR1]\]. The prevalence of chemotherapy-induced peripheral neuropathy (CIPN) can total 68% during the first month after the end of chemotherapy \[[@CR2]\], and its consequences are known to trigger excessive healthcare costs and resource use \[[@CR3]\].

Affected patients suffer from symptoms like pain and paraesthesia, loss of sensation and proprioception in the lower extremities resulting in muscle weakness, balance problems, and gait instability may lead to a higher risk of falling \[[@CR4]\]. Such functional impairments can substantially limit mobility \[[@CR5]\] and even predict hospitalization or mortality \[[@CR6]\]. Based on the ASCO guidelines, only duloxetine can currently be recommended for pain reduction in CIPN \[[@CR7]\]. The efficacy of further pharmacological and non-pharmacological approaches is not evidence-based \[[@CR7]\]. Therefore, we pursue further effective treatment options to ensure patients' social participation by preserving their mobility and reducing health risks that entail a prolonged need for therapy. There is cross-etiological evidence that exercising can reduce neuropathic symptoms \[[@CR8]\]: patients with diabetic neuropathy benefit from exercising like endurance \[[@CR9], [@CR10]\], balance \[[@CR11], [@CR12]\] and multimodal training \[[@CR13], [@CR14]\]. Endurance training induces metabolic changes, and balance training \[[@CR8]\] leads to neuronal adaptations and improved muscular output resulting in a better postural control \[[@CR15], [@CR16]\]. Concerning CIPN, exercising is generally recommended \[[@CR4]\] but has been less evaluated \[[@CR17]\]. Our intervention study on lymphoma patients provided initial indications about exercising and CIPN, where we speculated that especially balance exercises would reduce CIPN sensory symptoms and improve physical functioning \[[@CR18]\]. In our subsequent pilot study, exclusively CIPN patients underwent the aforementioned intervention and benefited from exercising by approximating the posture behavior of matched healthy control subjects (data unpublished). We thus implemented the present trial to evaluate exercise effects on CIPN symptoms and functional performance. Our primary objective was to improve CIPN patients' balance performance, hypothesizing that balance exercises would lead to a reduction in postural sway after a twelve-week intervention.

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

Fifty cancer survivors were randomly allocated consecutively between December 2013 and November 2014 to an intervention group (IG) or active control group (CG). Randomization in blocks of 10 was based on a computer-assisted pseudo-random number generator (Research Randomizer, Version 4.0). Allocation was implemented by sequentially numbered, sealed, opaque envelopes. After obtaining patient's consent, baseline measurement was performed and the next consecutively numbered envelope was opened afterwards.

Inclusion criteria were: reporting CIPN symptoms, completion of anti-tumor treatment, ≥18 years, a maximum 90 min' travel time to the Medical Center -- University of Freiburg, Germany, and written informed consent. Exclusion criteria were: neuropathies of different origin, severe cardiovascular diseases, instable bone metastases, and pregnancy. Pre- and post-assessments were made before (T0) and after (T1) intervention and took place at the Institute for Exercise- and Occupational Medicine, Medical Center -- University of Freiburg, Germany.

Lower-extremity CIPN was clinically confirmed by assessing reflexes and vibration sense and by discrimination tests for joint position sense, temperature, and pain sensation (Table [1](#Tab1){ref-type="table"}).Table 1Patients' characteristicIntention-to-treatPer-protocolAll\
*N* = 41IG vs. CG\
*P*IG\
*N* = 18CG\
*N* = 19All\
*N* = 37IG vs. CG\
*P*Age median (range)62 (44 -- 82)**0.025**70 (44 -- 82)60 (46 -- 75)63 (44 -- 82)**0.026**Sex m:f *N* (%)11 (27): 30 (73)4 (22): 14 (78)7 (37): 12 (63)11 (30): 26 (70)BMI median (range)25 (19 -- 42)0.37525 (19 -- 42)24 (21 -- 31)24 (19 -- 42)0.425Diagnosis *N* (%) Breast cancer14 (34)8 (44)4 (21)12 (32) Colorectal cancer14 (34)3 (17)10 (53)13 (35) Gynecological cancer other than breast4 (10)2 (11)1 (5)3 (8) Upper gastrointestinal cancer2 (5)1 (6)1 (5)2 (5) Non-small cell lung cancer1 (2)0 (0)1 (5)1 (3) Non-Hodgkin's lymphoma5 (12)4 (22)1 (5)5 (14) Multiple myeloma1 (2)0 (0)1 (5)1 (3)Therapies *N* (%) Surgery38 (93)16 (89)18 (95)34 (92) Radiation15 (37)8 (44)5 (26)13 (35) Hematopoietic cell transplantation2 (5)1 (6)1 (5)2 (5) Chemotherapy41 (100)18 (100)19 (100)37 (100)   *N* cycles, median (range)6 (1 -- 18)0.6816 (2 -- 6)6 (2 -- 16)6 (2 -- 16)0.775   *N* neurotoxic agents, median (range)2 (1 -- 4)0.1152 (1 -- 4)1 (1 -- 4)2 (1 -- 4)0.061   Therapy-free weeks, median (range)11 (1 -- 167)0.75410 (1 -- 167)18 (3 -- 98)13 (1 -- 167)0.775CIPN symptoms *N* (%)  Reduced vibration sense\*28 (70)13 (77)13 (68)26 (72)  Reduced joint position sense^\#^11 (28)5 (29)6 (32)11 (31)  Reduced temperature sensation^†^23 (58)12 (71)10 (53)20 (56)  Reduced pain sensation^†^4 (10)2 (12)2 (11)4 (11)  Loss of reflexes ASR / PSR28 (68) / 8 (20)12 (67) / 3 (17)13 (68) / 3 (16)25 (68) / 6 (16)Compliance %, median (range)92 (25 -- 100)0.17592 (71 -- 100)100 (71 -- 100)96 (71 -- 100)0.118\*measured on the first metacarpophalangeal joint, value \< 5 (scale 0--8); ^\#^measured on second toe, ≥ 3 failures out of 10 trials in random order; ^†^measured on arch, ≥ 3 failures out of 10 trials in random order; bold type indicates significance *P*\<0.05Abbreviations: *ASR* Achilles tendon reflex, *PSR* patellar tendon reflex, *IG* intervention group, *CG* control group, *BMI* body mass index, *CIPM* chemotherapy-induced peripheral neuropathy

This study was approved by the Ethics Committee of the University of Freiburg, conducted according to the Declaration of Helsinki and registered in the German Clinical Trials Register (DRKS00005419).

Interventions {#Sec4}
-------------

The one-on-one training sessions took place twice per week over 12 weeks in the division of Sports Oncology in the Clinic of Internal Medicine I. Both groups underwent endurance training up to 30 min of moderate intensity below the individual anaerobic threshold (IAT) on a stationary bicycle. The IG also did 30 min' balance training. Balance exercise sessions included three to eight exercises with three repetitions each à 20 -- 30s involving progressively increasing exercise difficulty by reducing the support surface and visual input, adding motor/cognitive tasks, and instability induction \[[@CR19]\].

For both groups, we additionally monitored exercise intensity by the perceived exertion rating scale \[[@CR20], [@CR21]\].

Furthermore, we controlled each patient's blood pressure and heart rate during each training session to avoid overload and documented vital parameters, training progress and reasons for missed sessions.

Outcome measures {#Sec5}
----------------

### Functional performance {#Sec6}

All the measurements were performed on a force plate (Leonardo Mechanograph® GRFP, Novotec Medical GmbH, Pforzheim, Germany), which determined dynamic ground reaction forces in its local and temporal progress. For balance assessments, we recorded the center of force sway path (mm) during three different stance conditions: semi-tandem stance with eyes open (ST~EO~) (primary endpoint) and eyes closed (ST~EC~), and monopedal stance (MS~EO~) over a period of 30s with a sample rate of 800 Hz. While measuring, patients were asked to stand upright and comfortably and direct their gaze onto a marked spot located at eye level on the wall. The best trial out of three was used for analysis. A reduction of sway path after exercising is associated with an improved postural control.

Additionally, we recorded the duration (max. 30s) patients could stand on one leg on a stable (MS~EO~) and unstable (MS~EOunstable~) surface, respectively.

To evaluate the lower body's muscle power, patients performed a maximum counter-movement jump to measure maximum power output during take-off per kilogram body weight (P~max_jump~; W/kg) and jumping height (cm). Patients were instructed to jump as high as possible. The best trial of two trials was used for analysis.

Data were analyzed using Leonardo Mechanography Research-Software (Novotec Medical GmbH, Pforzheim, Germany).

### CIPN symptoms and quality of life {#Sec7}

Vibration sense was determined on the first metacarpophalangeal joint, knuckle and patella via Rydel-Seiffer tuning fork with a graduating scale from 0 (no sensitivity) to 8 (highest sensitivity); due to reliability, tests were repeated twice, the respective mean value was used for analysis. For patients' characteristic, reduced vibration sense was defined as \< 5 \[[@CR22]\].

We used the EORTC QLQ-C30-questionnaire (European Organization for Research and Treatment of Cancer Quality of Life) to assess global quality of life (QoL). A higher score (max 100%) represents a higher quality of life \[[@CR23]\]. The module EORTC QLQ-CIPN20 and neurotoxicity subscale (NtxS) of FACT&GOG (Functional Assessment of Cancer Therapy/Gynaecology Oncology Group) were used to estimate CIPN severity. For CIPN20, we calculated a sum score and five sub-scores (sensory, motor, autonomic, upper and lower extremity). Each sub-score ranges from 0 to 100, where higher scores represent more severe symptoms or impairment.

### Cardiorespiratory fitness {#Sec8}

We determined cardiorespiratory fitness by peak oxygen consumption (V̇O~2peak~; mL·min^− 1^**·**kg^− 1^), maximum power output (P~max_CPET~; W/kg) and performance at the IAT (W/kg) measured during the maximum cardiopulmonary exercise test (CPET). CPET \[[@CR24]\] including electrocardiogram and blood pressure measurement took place on an electronically-braked cycle ergometer (Ergoline 900, Bitz, Germany) in recumbent position, starting at 20 watt and increasing stepwise by 10 watt every minute until exhaustion \[[@CR21]\]. Gas exchange and ventilation was continuously recorded by a breath-by-breath gas analysis system (Oxycon Delta, Jaeger, Hochberg, Germany). IAT was determined by analyzing the lactate concentration per step (Ergonizer, Freiburg, Germany).

Sample size and statistics {#Sec9}
--------------------------

Sample size calculation is based on the primary endpoint sway path at T1 and aims to detect a mean difference of 30% (SD ± 32%) between groups according to pilot study results. For sample size purposes, sway path is calculated as % of baseline measurement. With these prerequisites, 20 patients per group are required to provide 80% power to obtain a significant study result, using the 2-sided *t*-test with α = 0.05. Considering a maximum dropout rate of 20%, total sample size was set to *N* = 50. As specified in the clinical trial protocol, our primary analysis was conducted via regression model for variable ST~EO~ at T1 as dependent variable, treatment allocation and baseline ST~EO~ as covariates. Patients on whom we had no post-randomization data were excluded from the intention-to-treat analysis (Fig. [1](#Fig1){ref-type="fig"} Flowchart). A sensitivity analysis of the primary endpoint included the therapy-free time until study inclusion and patient age as additional covariates.Fig. 1Flow diagram for participants included in study

We also conducted a per-protocol analysis that excluded patients with training compliance \< 70%, calculated as completed training sessions divided by planned training sessions. All variables were tested non-parametrically as the assumption of normal distribution (Shapiro-Wilk test) was not satisfied. Differences between our two subject subpopulations at T0 and T1 and differences in the groups' delta (T1-T0) were assessed by Mann-Whitney-U-test. Intragroup differences over time were computed by Wilcoxon signed-rank test. The level of significance was set to *p* \< .05. To estimate the treatment effect, the point estimate and 95% confidence interval (CI) of the Hodges-Lehmann's median differences for paired groups were used. We also calculated the Phi coefficient (r~φ~= $\documentclass[12pt]{minimal}
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                \begin{document}$$ \sqrt{z2/n} $$\end{document}$) for effect sizes based on z-statistics of Wilcoxon- and Mann-Whitney-U test, respectively \[[@CR25]\]. IBM SPSS software (version 24; SPSS Inc., Chicago, Illinois, USA) was used for all analyses.

Results {#Sec10}
=======

No adverse events were observed during the study period. As post-randomization data were unavailable on seven patients, and two patients were excluded due to recruiting failure, our intention-to-treat analyses (ITT) included 41 patients. The primary analysis linear regression model (ITT) did not reveal a sway-path group difference (CG minus IG) at T1 (estimated as 35 mm; 95%CI -30 -- 101; *p* = .279), adjusted for baseline. The sensitivity analysis revealed that the covariates therapy-free time until study inclusion and patients' age did not lead to a fundamentally different interpretation of our results (see Table [2](#Tab2){ref-type="table"} for regression analysis results).Table 2Influence of group on "STEO sway path (mm) at T1" based on the regression analysisModel including as additional covariatesEstimated group difference for ST~EO~ sway path (mm) at T195% CI*P*Primary analysis model (ITT) including ST~EO~ sway path at T034.5-30.0 -- 100.90.279Sensitivity analysis model including additionally Patients' age30.4\*-38.1 -- 98.80.088 Therapy-free time until study inclusion27.9\*-36.2 -- 91.90.384Per-protocol analysis model including ST~EO~ sway path at T032.5\*-41.1 -- 106.00.376Regression analysis according to the intention-to-treat- (n = 41) and per-protocol principle (n = 37); independent variable: group; dependent variable: "STEO sway path (mm) at T1"; \*adjusted for STEO sway path at T0Abbreviations: *STEO* semi-tandem stance with eyes open, *CI* confidence interval

As not all patients attained ≥70% compliance, we present a per-protocol-analysis (*n* = 37) to describe the treatment effect in this group (see Table [3](#Tab3){ref-type="table"} and the following). We noted similar baseline values in the IG and CG, except for semi-tandem stance with eyes open, monopedal stance on instable surface and jumping performance, where the CG performed better in each case (ST~EO~: *P* = .049; MS~EOunstable~: *P* = .011; P~max_jump~: *P* = .019; Jumping height: *P* = .045).Table 3Results of per-protocol analysis (*N* = 37)T0 median (range)T1 median (range)median difference\* (95% CI)*P*r~ϕ~Balance performance ST~EO~ sway path (mm)IG628 (477 -- 1339)616 (420 -- 1261)-76 (-141 -- -17)**0.018**0.56CG572 (326 -- 928)578 (319 -- 809)-6 (-52 -- 50)0.8410.05*P***0.049**0.327**0.049** ST~EC~ sway path (mm)IG1290 (735 -- 4661)1486 (804 -- 4885)-32 (-205 -- 142)0.7170.09CG1466 (649 -- 3089)1342 (607 -- 2736)39 (-115 -- 160)0.8090.06*P*0.7810.4080.659 MS~EO~ sway path (mm)IG1755 (1255 -- 2440)1667 (1058 -- 3216)-204 (-442 -- 178)0.2140.41CG1510 (844 -- 2701)1303 (711 -- 2266)-204 (-367 -- 2)0.0560.51*P*0.3110.0591.000 MS~EO~ duration (sec)IG30 (1 -- 30)30 (18 -- 30)1 (0 -- 7)0.0510.49CG30 (11 -- 30)30 (7 -- 30)0 (0 -- 2)0.5000.15*P*0.2850.7070.230 MS~EOunstable~ duration (sec)IG10 (4 -- 30)30 (5 -- 30)11 (8 -- 17)**0.001**0.80CG30 (4 -- 30)30 (5 -- 30)0 (0 -- 5)0.2230.30*P***0.011**0.845**0.000**Jumping performance P~max_jump~ (W/kg)IG23 (15 -- 42)23 (15 -- 42)0.3 (-0.9 -- 1.6)0.5690.14CG28 (16 -- 48)29 (18 -- 49)1.3 (0.2 -- 2.2)**0.044**0.50*P***0.019**0.0580.539 Jumping height (cm)IG21 (13 -- 46)22 (13 -- 42)1 (-0.4 -- 3.2)0.1270.38CG29 (10 -- 45)28 (17 -- 47)2 (0.5 -- 3.5)**0.017**0.59*P***0.045**0.0680.838Vibrations sense (scale 0--8) First metacarpophalangeal jointIG2.5 (0.0 -- 7.5)3.4 (0.0 -- 8.0)0.4 (-0.3 -- 1.3)0.1390.36CG4.0 (0.0 -- 7.8)4.5 (0.5 -- 6.6)0.4 (-0.1 -- 0.9)0.0830.40*P*0.0710.1110.950 KnuckleIG3.8 (0.0 -- 7.3)4.1 (0.0 -- 8.0)0.0 (-1.1 -- 0.9)0.9770.01CG4.9 (0.0 -- 7.0)5.4 (0.0 -- 7.0)0.8 (0.3 -- 1.3)**0.017**0.55*P*0.471**0.049**0.175 PatellaIG5.0 (0.0 -- 8.0)4.3 (0.0 -- 7.3)-0.8 (-2.0 -- 0.0)**0.041**0.50CG4.8 (0.0 -- 6.5)5.6 (0.8 -- 7.0)1.0 (0.4 -- 1.6)**0.002**0.71*P*0.196**0.0050.000**Quality of life (%) Global QoLIG63 (17 -- 100)79 (33 -- 100)8 (-4 -- 17)0.0820.39CG67 (17 -- 100)67 (50 -- 100)4 (-4 -- 13)0.3070.23*P*0.8450.2210.461Subjective CIPN symptoms CIPN20 sum score^\#^IG28 (6 -- 85)20 (9 -- 69)-10 (-17 -- -4)**0.007**0.65CG28 (4 -- 70)24 (4 -- 63)-6 (-11 -- -1)**0.027**0.52*P*0.7820.4990.257 CIPN20 sensory score^\#^IG41 (4 -- 85)26 (4 -- 74)-7 (-15 -- 0)**0.028**0.53CG38 (7 -- 74)30 (7 -- 70)-7 (-15 -- 0)**0.018**0.56*P*0.9351.0000.925 CIPN20 motor score^\#^IG25 (0 -- 79)8 (0 -- 63)-8 (-18 -- 0)**0.006**0.67CG17 (0 -- 71)13 (0 -- 62)-2 (-6 -- 2)0.2780.26*P*0.5460.9160.114 CIPN20 autonomic score^\#^IG17 (0 -- 83)0 (0 -- 50)-8 (-17 -- 0)**0.006**0.65CG14 (0 -- 83)17 (0 -- 33)-6 (-17 -- 0)0.1510.34*P*0.7910.1180.313 CIPN20 upper extremity score^\#^IG19 (0 -- 91)14 (0 -- 81)-7 (-14 -- 2)0.0630.45CG19 (0 -- 71)19 (0 -- 62)-3 (-7 -- 1)0.0590.45*P*0.9610.6410.616 CIPN20 lower extremity score^\#^IG33 (8 -- 96)25 (0 -- 79)-13 (-19 -- -4)**0.007**0.66CG29 (8 -- 75)25 (8 -- 71)-8 (-15 -- -2)**0.014**0.58*P*0.5030.9640.552 NtxS score^†^IG29 (11 -- 40)32 (15 -- 41)3 (1 -- 6)**0.015**0.59CG31 (16 -- 39)31 (19 -- 40)2 (0 -- 4)0.0640.42*P*0.6200.9400.361Cardiorespiratory fitness V̇O~2peak~ (mL·min^−1^**·**kg^−1^)IG21 (16 -- 35)23 (17 -- 33)0.2 (-1.7 -- 1.7)0.6500.15CG23 (17 -- 54)25 (16 -- 54)1.4 (-0.4 -- 3.5)0.1330.35*P*0.3690.2420.417 P~max_CPET~ (W/kg)IG1.4 (0.9 -- 2.4)1.5 (0.8 -- 2.4)0.1 (0.0 -- 0.2)**0.025**0.53CG1.6 (0.9 -- 3.4)1.7 (0.9 -- 3.5)0.1 (0.0 -- 0.2)**0.004**0.66*P*0.4080.2450.443 IAT (W/kg)IG1.1 (0.6 -- 2.0)1.1 (0.6 -- 1.8)0.1 (-0.2 -- 0.1)0.1220.36CG1.1 (0.5 -- 2.6)1.3 (0.8 -- 2.6)0.1 (0.0 -- 0.1)**0.020**0.54*P*0.3740.3580.707Notes: \* prescribes the treatment effect by point estimation and 95% confidence interval of the Hodges-Lehmann's median differences for paired groups; \# scoring from 0 (no symptoms) -- 100 (severe symptoms); † scoring from 0 (severe symptoms) -- 44 (no symptoms); bold type indicates significance *P*\<0.05Abbreviations: *T0* pre intervention, *T1* post intervention, *CI* confidence interval, *P p*-value, *rϕ* Phi coefficient, *STEO/ EC* semi-tandem stance with eyes open/closed, *MSEO/EOunstable* Monopedal stance with eyes open on unstable surface, *Pmax_jump/CEPT* maximum power output during jumping/CEPT, *CEPT* cardiopulmonary exercise test, *QoL* quality of life, *CIPN20* module of the EORTC-QLQ (European Organization for Research and Treatment of Cancer Quality of Life) questionnaire, *NtxS* neurotoxicity subscale of FACT/GOG (Functional Assessment of Cancer Therapy/Gynaecology Oncology Group), *V̇O*~2peak~ peak oxygen consumption, *IAT* individual anaerobic threshold, *IG* interventions group, *CG* control group

Functional performance {#Sec11}
----------------------

IG's ST~EO~ sway path decreased significantly (− 76 mm, 95%CI -141 -- -17; *p* = .018), while the CG's was unchanged, leading to a significant difference in groups' delta (*p* = .049). ST~EC~ sway path revealed no inter- or intragroup changes. In the monopedal stance condition (MS~EO~ sway path), both groups improved descriptively without statistical significance, but with moderate effect sizes (r~φ~ = 0.41; r~φ~ = 0.51, respectively). However, only the IG improved their time standing on one leg (MS~EO~: 1 s, 95%CI 0--7; *p* = .051; MS~EOunstable~: 11 s, 95% CI 8--17; *p* = .001), while the CG maintained their performance level, leading to a significant difference in groups' delta for MS~EOunstable~ (*p* = .000).

CG improved their maximum jump height significantly (2 cm, 95%CI 0.5--3.5; *p* = .039), while the IG's failed to change. Maximum power (P~max_jump~) was unaltered.

CIPN symptoms and quality of life {#Sec12}
---------------------------------

We detected neither inter- nor intragroup differences in vibration sense measured on the first metacarpophalangeal joint (scale 0--8). However, on the knuckle, the CG increased significantly (0.8, 95% CI 0.3--1.3; *p* = .011) leading to a significant group difference at T1 (*p* = .049). Furthermore, the patella's vibration sense improved significantly in the CG (1.0, 95% CI 0.4--1.6; *p* = .002), while the IG's decreased significantly (− 0.8, 95% CI -0.2 -- 0.0; *p* = .041), leading to a significant difference at T1 (*p* = .005) and in groups' delta (*p* = .000).

In NtxS, the IG reported significantly alleviated CIPN symptoms (3, 95% CI 1--6; *p* = .015). Except for the upper extremity sub-score, CIPN20 revealed significant weakening in the IG's CIPN symptoms (sum score: -10, 95% CI -17 -- -4; *p* = .007; sensory score: -7, 95% CI -15 -- 0; *p* = .028; motor score: -8, 95% CI -18 -- 0; *p* = .006; autonomic score: -8, 95% CI -17 -- 0; *p* = .006; lower extremity score: -13, 95% CI -19 -- -4; *p* = .007), while the CG's sum, sensory and lower extremity scores also decreased significantly (− 6, 95% CI -11 -- -1; *p* = .027; − 7, 95% CI -15 -- 0; *p* = .018; − 8, 95% CI -15 -- -2; *p* = .014; respectively). Both groups' global QoL improved slightly but not significantly.

Cardiorespiratory fitness {#Sec13}
-------------------------

The CG significantly improved their performance at IAT after the intervention (0.1 W/kg, 95%CI 0.0--0.1; *p* = .020; no change for IG *p* = .122). Furthermore, both groups strengthened their maximum power output (IG: 0.1 W/kg, 95%CI 0.0--0.2; *p* = .025; CG: 0.1 W/kg, 95%CI 0.0--0.2; *p* = .004). However, we detected no differences in V̇O~2peak~.

Discussion {#Sec14}
==========

The aim of this randomized controlled clinical trial was to assess the effects of endurance and balance training on CIPN symptoms and the physical function of cancer survivors after treatment. Primary intention-to-treat analysis did not reveal a superiority of balance training contrary to our hypothesis. However, subsequent analysis did not entirely support this finding, since the results of per-protocol analysis (≥70% compliance) including secondary endpoints requires a detailed view. For this analysis, however, the number of patients is under the 20 patients per group required according to the power analysis. Our results may have been more convincing with a larger number of patients.

In general, balance training is known to induce neuronal adaptations and improve muscular output leading to an enhanced postural control \[[@CR15], [@CR16]\]. It is well known that patients with a proprioceptive deficit such as peripheral neuropathy suffer from postural instability \[[@CR5]\], as do patients with CIPN \[[@CR26]--[@CR31]\]. However, only four randomized controlled trials have been published on the effects of balance interventions in CIPN patients \[[@CR18], [@CR32]--[@CR34]\]. Our trial showed that our IG prolonged their standing time on one leg, and reduced their sway path in the semi-tandem stance with eyes open -- factors associated with better postural control \[[@CR28]\]. Even our CG slightly improved their balance performance in the monopedal stance without having practiced this task. This improvement could be traced back to a general increase in leg-muscle strength induced by endurance training, a factor also reflected by our finding that both groups enhanced their maximum power output during CEPT. However, only CG's jumping performance increased. Since both groups formally completed the same endurance training, such a change should probably have been observed in both groups. It is conceivable that the CG engaged more intensively in their endurance training, since their training program consisted exclusively of endurance training, which may unconsciously lead to more intense training, while the IG may have considered the 30-min endurance exercise to be a mere warm-up. A further explanatory viewpoint lies in the baseline differences; the CG exhibited greater power capacity already at T0, ie, P~max_jump~ and jump height, than did the IG.

This baseline difference may be attributable to the CG's younger age, since the rate of force development is known to decline with age \[[@CR35]\]. The CG's younger age may also be responsible for the significant baseline difference in two balance tasks, MS~EOunstable~ and ST~EO~. Their predominant initial functional status may also be because they received a lower amount of neurotoxic agents.

In the eyes-closed condition in the balance tasks, we detected no inter- or intragroup differences, but the sway path increased considerably after closing the eyes. The increase in postural sway when visual information is unavailable is more pronounced in patients with neuropathy than in healthy subjects \[[@CR5]\]. These patients may rely more on vestibular signals, which are known to carry a larger amount of noise \[[@CR36]\] than on diminished proprioception to stabilize the posture. At this point, we cannot conclusively clarify how severely diminished our patients' proprioception was, as we did not compare their balance performance to healthy subjects, especially the rise in sway from eyes open to closed. Most of our patients suffered from a reduced vibration sense and reported having more sensory than motor symptoms. Axon degeneration in unmyelinated distal nerve endings seems to be the central pathology of CIPN \[[@CR37]\], responsible especially for sensory symptoms \[[@CR38]\]. However, we assume that stimulus conduction is not completely dysfunctional: large myelinated nerve fibers carrying proprioceptive information and inducing muscular output might be less affected. Additionally, exercising may have stimulated the use of less damaged pathways. The increase in maximum power output in both groups and their improvements in balance performance might support this hypothesis and indicate that neuromuscular adaptation is possible. However, we observed no improvements in the eyes-closed conditions, which made us conclude that patients did not change their posture strategy towards reducing vestibular in favor of proprioceptive cues. We thus suggest focusing even more strongly on exercises without visual input during training. Being aware that analyzing CIPN20 sub-scores remains controversial \[[@CR39]\], our motor-score results may reflect neuromuscular adaptation, as our IG improved considerably. Interestingly, both groups experienced reduced sensory symptoms and greater improvements in their lower extremities, since both exercises obviously targeted the lower body more strongly than the upper. However, objectively, only in the CG did we detect a significantly improved vibration sense from proximal to distal - probably attributable to their lower exposure to neurotoxic agents. Animal models have shown that increased blood flow, and an enhanced overall metabolic rate thanks to endurance training might result in higher levels of neurotrophic factors that may induce nerve regeneration \[[@CR40], [@CR41]\] and thus possibly reduce sensory symptoms. Furthermore, the anti-inflammatory effect of exercise might have contributed to weaker sensory symptoms \[[@CR41]\].

Endurance training did not just affect CIPN-specific symptoms - it also resulted in improved performance in the CG's IAT, presumably because of their more intensive endurance training as mentioned above. This increase in endurance capacity was not confirmed in our V̇O~2peak~ findings. Both groups improved their maximum performance during CPET, possibly due to a general strength increase. This strength increase is also apparent in the CG's jump height, but here without affecting power output. Muscular power output, as jumping requires, is strongly associated with mobility and functional ability \[[@CR35]\], factors impaired in CIPN patients. We thus propose to focus also on power training to alleviate functional disabilities in CIPN patients \[[@CR42]\] and to counteract the CIPN-induced acceleration of neuromuscular degeneration.

The fact that both groups showed improvements suggests that both interventions are potentially effective in addressing different aspects of CIPN. However, the reader should take note that a placebo effect cannot be definitively ruled out in this study. As other RCTs have also demonstrated positive effects in their intervention groups by including an inactive control group \[e.g. 32,34\], we assume that the improvements we observed are genuine effects rather than placebo effects. Furthermore, we suppose that group differences in patients' characteristic, i.e. age and amount of neurotoxic agents, may have influenced study results as discussed above. We therefore propose to stratify randomization according to those factors.

Conclusions {#Sec15}
===========

We assume that endurance training contributed to a reduction in sensory symptoms in our study patients, while the balance part additionally affected the neuromuscular system relevant to patients' functional status. This additional effect might reflect the IG's superiority in the CIPN20 motor score, as well as in NtxS. However, we suspect that a larger sample is needed to reveal stronger group differences. Furthermore, we propose to integrate a third study arm with no physical intervention, and to expand upon CIPN diagnostics. We conclude that both exercises present a clear and relevant benefit for patients with CIPN by improving their functional status and alleviating CIPN symptoms. As pharmacological treatment options are very limited, these exercise interventions can be considered an effective non-pharmacological treatment approach. We are convinced that neuromuscular adaptation is possible despite CIPN, and that it's never too late to start exercising.

CG

:   Control group

CIPN

:   Chemotherapy-induced peripheral neuropathy

CIPN20

:   Module of EORTC quality of life questionnaire

CPET

:   Cardiopulmonary exercise test

IAT

:   Individual anaerobic threshold

IG

:   Intervention group

MS~EO~

:   Monopedal stance

MS~EOunstable~

:   Monopedal stance on an unstable surface

NtxS

:   Neurotoxicity subscale of FACT&GOG

P~max_CPET~

:   Maximum power output during cardiopulmonary exercise test

P~max_jump~

:   Maximum power output during take-off

QoL

:   Quality of life

ST~EC~

:   Semi-tandem stance with eyes closed

ST~EO~

:   Semi-tandem stance with eyes open

W

:   Watt
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